Search / Trial NCT00000713

A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of July 27, 2024

Completed

Keywords

Polyribonucleotides Hiv Seropositivity Dose Response Relationship, Drug Drug Evaluation Acquired Immunodeficiency Syndrome Ampligen Aids Related Complex Antiviral Agents

Description

Evidence indicates that a long period with no symptoms follows infection with HIV. Individuals who are infected with the virus could benefit from therapy with a drug that acts to kill the virus or to stimulate the immune system of the individual or both. The immune system is the means the human body has for fighting infections. Ampligen is a suitable drug for clinical trials against HIV because it has been shown to stimulate the immune system and to inhibit HIV in vitro (test tube) at drug levels that can be achieved without noticeable clinical side effects. Individuals entered in the stud...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Short-course therapy (7 days) with oral acyclovir or ketoconazole.
  • Patients must have:
  • Evidence of HIV infection as measured by a confirmed positive antibody test.
  • A confirmed or pending HIV blood culture, and serum p24 antigen test.
  • The ELISA test confirmed by a licensed Western blot analysis if they are asymptomatic.
  • Exclusion Criteria
  • Concurrent Medication:
  • Excluded:
  • Aspirin or acetaminophen beyond 72 hours without contacting investigator.
  • Chemoprophylaxis for Pneumocystis carinii pneumonia (PCP).
  • Patients with the following are excluded:
  • AIDS.
  • AIDS related symptoms or with advanced ARC and < 200 CD4 cells/mm3 and at least two of the following:
  • Weight loss in excess of 10 lbs or 10 percent of body weight within a 6-month interval.
  • Temperature > 38.5 degrees C with or without night sweats, persisting for more than 14 consecutive days or more than 15 days in a 30-day interval.
  • Diarrhea defined as = or > 3 liquid stools per day, persisting for more than 30 days without definable cause.
  • Recurrent oral candidiasis as documented by morphology or by response to antifungal therapy.
  • Patients cannot have active oral candidiasis at the time of entry into the study; they must be free of candidiasis from baseline 1 to enrollment.
  • Multidermatomal herpes zoster within the past 2 years.
  • Hairy leukoplakia within the past 3 years.
  • Prior Medication:
  • Excluded within 14 days of study entry:
  • Other biologic response modifiers.
  • Corticosteroids.
  • Systemic antibiotics.
  • Excluded within 30 days of study entry:
  • Other antiretroviral agents.
  • Excluded within 60 days of study entry:
  • Ribavirin.
  • Zidovudine.
  • Concurrent neoplasms other than basal cell carcinoma of the skin.
  • Active drug or alcohol abuse.

Attachments

readout_NCT00000713_2024-07-27.pdf

4.5 MB

NCT00000713_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Pittsburgh, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0